Celsion presents Phase I/II DIGNITY trial data at 2010 Breast Cancer Symposium
Celsion Corporation announced today that interim data from its Phase I/II DIGNITY trial of ThermoDox in Recurrent Chest Wall (RCW) Breast Cancer were presented at the poster session at the 2010 Breast Cancer Symposium.